GLP1R and Parkinson disease: GLP-1R agonists, established therapeutics for T2DM, were previously shown to protect cognition; thus, liraglutide and exenatide are currently in clinical trials for AD and Parkinson's disease (PD), respectively (Kim et al., 2017; Batista et al., 2018; Cummings et al., 2018).